10 July 2026NewsBiotechMarisa Woutersen

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Biotech
16 October 2026   All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.
Biotech
29 September 2026   The gene-editing company has accused a former employee of secretly co-founding a Chinese biotech while still at the company, in a trade secrets lawsuit involving rival base-editing therapies and disputed patent filings.
Biotech
21 September 2026   Judges agreed with the Oxford University spin-out that MGI Tech was likely to infringe Oxford’s patent, and banned sales of certain Cyclone devices to preserve the one-player-market status quo.